ATEC Announces Pricing of Public Offering of Common Stock

Rhea-AI Summary

Alphatec Holdings, Inc. announces pricing of public offering of common stock

Positive

• Alphatec Holdings, Inc. has priced its underwritten public offering of 14,300,000 shares of common stock at $10.50 per share. The company expects to receive gross proceeds of approximately $150 million from the offering.

Negative

• None.

CARLSBAD, Calif.--(BUSINESS WIRE)-- Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the pricing of an underwritten public offering of 14,300,000 shares of its common stock at a public offering price of $10.50 per share. The offering is expected to close on October 27, 2023, subject to the satisfaction of customary closing conditions. In connection with the offering, ATEC has granted the underwriters a 30-day option to purchase up to an additional 2,145,000 shares of common stock in the offering at the public offering price, less underwriting discounts and commissions.

Morgan Stanley, TD Cowen, Barclays and Stifel are acting as joint book-running managers in the offering.

ATEC expects to receive gross proceeds from the offering of approximately $150 million, assuming no exercise of the underwriters’ option to purchase additional shares.

The shares of common stock are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-271336) previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”). A preliminary prospectus supplement and accompanying base prospectus relating to the offering, and a final prospectus supplement and accompanying base prospectus relating to the offering each contain important information relating to the ATEC’s shares of common stock. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. The final prospectus supplement and accompanying base prospectus will be filed with the SEC and available on the SEC’s website thereafter, and, when available, may also be obtained from Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Cowen and Company, LLC, 599 Lexington Avenue, New York, New York 10022, by telephone at (833) 297-2926 or by email at prospectus_ecm@cowen.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 1-888-603-5847 or by email at barclaysprospectus@broadridge.com.

This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About ATEC

ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation Machine™ is focused on developing new approaches that integrate seamlessly with the Company’s expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC’s vision is to be the Standard Bearer in Spine.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. ATEC cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. The words “believe,” “will,” “should,” “expect,” “intend,” “estimate,” “look forward” and “anticipate,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. Forward-looking statements include, but are not limited to, the Company’s expectations regarding the completion, timing and size of the proposed public offering. Important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to, risks and uncertainties related to market and other conditions and the satisfaction of customary closing conditions related to the proposed public offering. A further list and description of these and other factors, risks and uncertainties can be found in ATEC’s most recent annual report, any subsequent quarterly and current reports, and certain other filings, filed with the SEC. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231024018696/en/

Company Contact:

J. Todd Koning

Chief Financial Officer

investorrelations@atecspine.com

Investor/Media Contact:

Tina Jacobsen

Investor Relations

(760) 494-6790

investorrelations@atecspine.com

Source: Alphatec Holdings, Inc.

FAQ

What is the pricing of Alphatec Holdings' public offering of common stock?

Alphatec Holdings has priced its public offering of common stock at $10.50 per share.

How many shares of common stock are being offered?

Alphatec Holdings is offering 14,300,000 shares of common stock.

How much gross proceeds is the company expecting from the offering?

The company expects to receive gross proceeds of approximately $150 million from the offering.

Who are the joint book-running managers in the offering?

The joint book-running managers in the offering are Morgan Stanley, TD Cowen, Barclays, and Stifel.

Where can I find more information about the offering?

More information about the offering can be found in the preliminary prospectus supplement and accompanying base prospectus filed with the SEC and available on their website.